Oslo, Norway ,April 10, 2024 -EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, presented a poster at the prestigious annual meeting of theAmerican Association for Cancer Research (AACR ) onApril 9 . Dr.Udai Banerji , the principal investigator of the ACTIVATE study and Dr.Amir Snapir , Chief Medical Officer of EXACT Therapeutics presented the poster showcasing the results from the dose escalation part of the ACTIVATE study in patients with liver metastases of colorectal origin. The main conclusions are: o The results provide proof of concept that treatment with ACT® produces substantial reduction in tumour size in patients treated with standard of care chemotherapeutics. o The results do not show any unexpected side effects from ACT on its own or any worsening of the adverse effects of chemotherapy. Dr. Per Walday, CEO of EXACT Therapeutics comments: "The results of the dose escalation part of the ACTIVATE study are very encouraging, indicating that targeted treatment with ACT is both safe and effective. This is truly promising and I would like to thank the team for the great work leading up to this and the participating patients for their support." The ACTIVATE study is on track to be completed in 2024. The poster is also available here: https://exact-tx.com/publications-1-1 For more information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to enable or significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com About ACT® o ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. o ACT® is being tested in the clinic and has released positive interim data. It is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the Company is oncology. The ACT® platform has potential across many therapeutic areas (including CNS, immunotherapy) and product classes. Forward looking statements: This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source